Edo Naoki, Morita Koji, Suzuki Hisanori, Takeshita Akira, Miyakawa Megumi, Fukuhara Noriaki, Nishioka Hiroshi, Yamada Shozo, Takeuchi Yasuhiro
Endocrine Center, Toranomon Hospital, Tokyo, Japan.
Endocr J. 2016 May 31;63(5):469-77. doi: 10.1507/endocrj.EJ15-0569. Epub 2016 Mar 5.
Remission of acromegaly is defined as a nadir in GH <1.0 ng/mL during a 75-g oral glucose tolerance test (75gOGTT) and insulin-like growth factor-1 (IGF-1) normalization. Recently, a lower cut-off value for GH nadir (<0.4 ng/mL) has been proposed. We retrospectively evaluated the prevalence and clinical characteristics of postoperative cases with normalized IGF-1 levels and a GH nadir of 0.4-1.0 ng/mL one year after complete resection of GH-secreting pituitary adenoma (GHoma). We included 110 cases of acromegaly with complete adenoma resection, no preoperative treatment, preoperative glycosylated hemoglobin <6.5%, preoperative basal plasma glucose <126 mg/dL, GH nadir <1.0 ng/mL during a 75gOGTT, and normalized IGF-1 at the first postoperative year evaluation, whereupon patients were divided into two groups: control (GH nadir <0.4 ng/mL) and high GH (GH nadir >0.4 ng/mL). Clinical parameters, including measures of insulin secretion and resistance, were compared between groups. The high GH group included 10 patients (9.1%) and had a lesser level of insulin resistance immediately following surgery and at the first postoperative year evaluation. On single regression analysis, insulin resistance immediately following surgery was predictive of and correlated with the GH nadir at the first postoperative year evaluation. The GH nadir at the first postoperative year evaluation may be insufficient in patients with normalized IGF-1 with low insulin resistance immediately following complete resection of GHoma. Careful evaluation is needed to assess remission in such patients.
肢端肥大症的缓解定义为在75克口服葡萄糖耐量试验(75gOGTT)期间生长激素(GH)最低点<1.0 ng/mL且胰岛素样生长因子-1(IGF-1)恢复正常。最近,有人提出了更低的GH最低点临界值(<0.4 ng/mL)。我们回顾性评估了生长激素分泌型垂体腺瘤(GH瘤)完全切除术后一年,IGF-1水平恢复正常且GH最低点为0.4 - 1.0 ng/mL的术后病例的患病率和临床特征。我们纳入了110例肢端肥大症患者,这些患者腺瘤完全切除、术前未接受治疗、术前糖化血红蛋白<6.5%、术前基础血浆葡萄糖<126 mg/dL、75gOGTT期间GH最低点<1.0 ng/mL且术后第一年评估时IGF-1恢复正常,据此将患者分为两组:对照组(GH最低点<0.4 ng/mL)和高GH组(GH最低点>0.4 ng/mL)。比较了两组之间的临床参数,包括胰岛素分泌和抵抗的指标。高GH组包括10例患者(9.1%),术后即刻及术后第一年评估时胰岛素抵抗水平较低。单因素回归分析显示,术后即刻的胰岛素抵抗可预测并与术后第一年评估时的GH最低点相关。在GH瘤完全切除后,IGF-1恢复正常且术后即刻胰岛素抵抗较低的患者中,术后第一年评估时的GH最低点可能并不充分。对此类患者需要进行仔细评估以判断是否缓解。